'Treasure Hunt': Tourists Boost Sales at Japan's Don Quijote Stores

Business is booming at Japanese discount chain Don Quijote, which sells everything from compact gadgets to party costumes, thanks to its cult status among tourists. Richard A. Brooks / AFP
Business is booming at Japanese discount chain Don Quijote, which sells everything from compact gadgets to party costumes, thanks to its cult status among tourists. Richard A. Brooks / AFP
TT

'Treasure Hunt': Tourists Boost Sales at Japan's Don Quijote Stores

Business is booming at Japanese discount chain Don Quijote, which sells everything from compact gadgets to party costumes, thanks to its cult status among tourists. Richard A. Brooks / AFP
Business is booming at Japanese discount chain Don Quijote, which sells everything from compact gadgets to party costumes, thanks to its cult status among tourists. Richard A. Brooks / AFP

Business is booming at Japanese discount chain Don Quijote, which sells everything from nostril-hair wax to compact gadgets and colorful party costumes, thanks to its cult status among tourists but also inflation at home.

At a large Don Quijote store in Tokyo's bustling Shibuya district, hundreds of tourists rush to fill their baskets with snacks and souvenirs from its heaving narrow aisles.

"I was pretty overwhelmed at first, just because there's so many options, everything's in a different language," 27-year-old Garett Bryan from the United States told AFP.

But "I feel like I bought a lot and it was only like $70" including "a coffee cup for my mom, a fan, some Godzilla chopsticks, just a couple toys".

The chaotic cut-price shops nicknamed "Donki" were founded in the 1980s by Takao Yasuda, who named them after his business inspiration: the idealistic protagonist of the classic Spanish novel, "Don Quixote".

He wanted to shake up Japan's staid retail industry with new tactics including late-night opening hours as well as more varied prices and product lines.

Now a record influx of visitors to Japan, fueled by a weak yen, is boosting sales nationwide.

Revenues at Don Quijote in Japan are "around 1.7 higher than before the pandemic", said Motoki Hata, a manager at the retailer.

Last year its parent firm Pan Pacific International Holdings (PPIH) saw revenue rise around 12 percent year-on-year for its discount chains including Donki, while tax-free sales beat internal forecasts.

Shopping at Don Quijote is like a "treasure hunt" -- a fun experience that foreign visitors love, Hata told AFP.

"Customers end up buying something different than what they came in for," he said beside rows of cherry-blossom flavor KitKats, a popular exclusive product.

- 'Jungle'-like -

Don Quijote and its sister brands have 501 stores in Japan, where 24 new ones opened during the past financial year.

PPIH Group also runs 110 stores abroad, in the United States and across Asia from Taiwan to Thailand.

California is one place being targeted by the company for expansion, according to analyst Paul Kraft, founder of Tokyo-based consultancy firm JapanIQ.

But that plan could be complicated by US President Donald Trump's trade tariffs -- including levies of 24 percent on Japan, which have been paused until July.

Even so, "I wouldn't bet against them, even in this entire high-tariff environment", Kraft said.

"Nobody adjusts as fast as Don Quijote in retail in Japan -- even faster than convenience stores, because they give so much autonomy to their stores."

They are also "some of the smartest and most aggressive buyers that I've seen", with consistently "the best selection of almost anything".

However, in Japan at least, the shopping experience is "cramped, dark, you know, the buildings might be old" with products seemingly "hanging from everywhere".

Don Quijote's omnipresent Santa-hat wearing penguin mascot Donpen and its "Don Don Donki" jingle on repeat just adds to the "jungle"-like experience.

"It is just almost an assault on the senses," Kraft said.

- Inflation hits -

Still, Don Quijote "has grown to be an extremely important retailer in Japan", Kraft said -- especially as rising inflation ramps up demand for cheaper products.

The country's core inflation rate accelerated to 3.2 percent in March, with consumers feeling the pinch on electricity bills as well as kitchen staples like cabbage and rice.

Household consumption fell 1.1 percent in 2024, with some people making the trip to Don Quijote to save.

"It's less expensive than other shops, and they also have famous brands," said a Tokyo resident who shops at the store twice a week and gave her surname as Kuroki.

Shoji Raku, 20, told AFP she shops at Donki for "shampoo, electronics and everything that you don't find elsewhere".

There is even usually a cordoned off adults-only section at Donki stores selling various sex toys.

Tourist sales remain a key focus for the chain, which plans to open two new stores targeted at visitors in Japan next year, centered on duty-free products.

But one Donki customer, Bruno Bosi from Brazil, said shoppers should tread with caution.

"It is a store for you to buy as much as you want -- but I think you need to ask yourself if you need it," he said.



Mexican Baby Monkey Finds Comfort in Plush Companion

A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
TT

Mexican Baby Monkey Finds Comfort in Plush Companion

A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)

Yuji, a 6-week-old patas monkey in Mexico, wakes up every day clinging to a stuffed dog. More than a toy, this plush companion acts as a surrogate mom after the tiny primate was rejected by his own mother, Kamaria, a first-time parent unable to form a maternal bond.

Weighing a mere 673 grams (1.4 pounds), Yuji represents the most recent case of assisted rearing at the Guadalajara Zoo in western Mexico.

The story of Yuji has captured the attention of the Mexican public, drawing parallels to Punch, the Japanese macaque that went viral on social media after growing up clinging to a stuffed orangutan following his mother’s rejection, The Associated Press reported.

Unlike Punch, Yuji has not yet had physical contact with other members of his species; he spends most of his time inside a monkey crate at the Guadalajara Zoo’s Comprehensive Center for Animal Medicine and Welfare, CIMBA, where he is under the care of 12 veterinarians and biologists.

No date has been set for Yuji’s transfer to a habitat shared by 12 other adult patas monkeys and three other infants. That will depend on when he is weaned from a milk-only diet and starts an adult diet complete with fruits and vegetables, said veterinarian Iván Reynoso Ruiz, head of the primate section at the Guadalajara Zoo. That could happen when Yuji is around 6 months old, he said.

Just hours after giving birth on March 3, Kamaria began exhibiting irregular behavior. She struggled to hold her firstborn correctly, leaving the infant unable to secure a grip on its mother.

After noticing a problem, keepers separated the mother from her newborn, who weighed just 443 grams (less than a pound) and required immediate placement in an incubator at CIMBA to stabilize his temperature and safeguard his health, Reynoso Ruiz said.

This was the start of the infant's assisted rearing, a process often used by zoos to protect the health and development of at-risk offspring. A caregiver named him Yuji after a popular Japanese manga character.

During his first few weeks, Yuji was under round-the-clock supervision and was bottle-fed fortified milk.

From the start, Yuji was given a stuffed animal for comfort. Reynoso Ruiz explained that the toy fulfills the role of a mother by serving as his primary source of security. To maintain hygiene, staff rotate the original stuffed dog with two other toys — a bear and a monkey — to ensure he always has a clean companion.

To stimulate his development, caregivers outfitted Yuji’s crate with a small hammock and ropes. As he began gaining weight and sleeping for longer intervals, his team adjusted his feeding schedule. Yuji now receives the first of his four daily bottles at 7:00 a.m.

While the stories of Punch and Yuji have been popular on social media, some animal rights advocates oppose the practice of assisted rearing.

Diana Valencia, an animal rights activist, argues that there is no substitute for a natural habitat, and that animals “have the right to be born, grow, develop, and die where they belong.”

Responding to these criticisms, the Guadalajara Zoo’s primate expert emphasized that modern zoos provide a unique opportunity to protect species from global threats. He said the intervention was a matter of life or death, and that Yuji likely would have perished in the wild without a “second chance” at survival.


Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
TT

Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP

It's been dubbed the "Arc de Trump." But now President Donald Trump's latest building project has an official name -- the "United States Triumphal Arch."

White House Press Secretary Karoline Leavitt revealed the formal title on Wednesday, saying the giant structure was being built to mark the 250th anniversary of US independence, AFP reported.

"In honor of this historic occasion, President Trump and the Department of Interior will submit plans for the United States Triumphal Arch," Leavitt told reporters.

Showing off a picture that she initially held upside down, Leavitt said the "monumental" arch would stand 250 feet (76.2 meters) tall "in honor of 250 years."

Its colossal height, including a huge golden Lady Liberty statue on top, means it will dwarf perhaps its most famous predecessor, the Arc de Triomphe in Paris, which stands at 164 feet.

In fact it is set to be the largest structure of its kind in the world, pipping Mexico City's Monument to the Revolution and knocking Pyongyang's Arch of Triumph to third place.

Plans for the arch were first revealed in October when AFP journalists spotted a model on Trump's desk in the Oval Office, after which it was quickly dubbed the "Arc de Trump" by US media.

Trump revealed the first full renderings for the structure last Friday.

The arch is one of several architectural projects -- including the construction of a gigantic White House ballroom and renovations to the Kennedy Center for the Performing Arts -- that Trump has undertaken to leave a mark on Washington in his second term.

Critics say the gold-accented arch, which will tower over the 99-foot-tall Lincoln Memorial, is a monument to the 79-year-old Trump's vanity.

The arch will partly be funded by US taxpayers, getting $2 million in special funds from the US National Endowment for the Humanities, with up to $13 million in funds to match any donations, ABC News reported.

But Leavitt said it was aimed at celebrating US national pride.

"Long after everyone in this room is gone, our children and grandchildren will remain inspired by this national monument," she told reporters.


Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
TT

Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.

The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer's patients.

Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year, said AFP.

After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.

Both drugs were approved by the United States and European Union over the last few years.

However concerns about their effectiveness, cost and side effects including an increased risk of brain swelling and bleeding have since prompted caution. State-run health services in the UK and France have refused to cover the drugs.

The new Cochrane review combined data from 17 clinical trials that included a total of more than 20,000 people with mild cognitive impairment or early dementia.

The trials, which took place over roughly 18 months, studied seven different anti-amyloid drugs.

Only one of the trials examined donanemab -- sold under the name Kisunla by US pharma giant Eli Lilly -- while one studied lecanemab, sold as Leqembi by Biogen and Eisai.

While early trials suggested these drugs made a statistically significant difference, this did not translate into "something clinically meaningful for patients," lead study author Francesco Nonino of Italy's IRCCS institute told a press conference.

Brain scans showed that the drugs successfully removed amyloids, the researchers emphasized.

This means "the idea that removing amyloids will benefit patients was refuted by our results," said study co-author Edo Richard of Radboud University Medical Center in the Netherlands.

- 'Not delivering on promise' -

Richard, who has previously expressed skepticism about anti-amyloid drugs, said he hopes efforts targeting other mechanisms that potentially cause Alzheimer's lead to more effective drugs in the future.

British biologist John Hardy, who first developed the amyloid hypothesis in the 1990s, criticized the review for lumping together data about lecanemab and donanemab along with drugs that are known to be ineffective, therefore dragging down the overall average.

"This is a silly paper which should not have been published," Hardy told AFP, disclosing that he has consulted for Eli Lilly, Biogen and Eisai.

In response to such questions, Richard said that while the drugs included in the study may work in different ways, they all have the same target: amyloid beta proteins.

Australian neuroscientist Bryce Vissel, who was not involved in the research, said it "does not prove amyloid has no role in Alzheimer's, and it does not rule out future amyloid-directed therapies that may yet help patients".

"But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it."